Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 1Phase 2 Interventional Results available

Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer

ClinicalTrials.gov ID: NCT04345913

Public ClinicalTrials.gov record NCT04345913. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 2:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I/II Trial Evaluating the Safety and Efficacy of Eribulin in Combination With Copanlisib in Patients With Metastatic Triple Negative Breast Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This phase I/II trial studies the side effects and best dose of copanlisib and how well it works when given together with eribulin in treating patients with triple negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Copanlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as eribulin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving copanlisib and eribulin together may work better in treating advanced stage triple negative breast cancer compared to eribulin alone.

Study identification

NCT ID
NCT04345913
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 1, Phase 2
Enrollment
24 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 1, 2021 (Actual)
Primary completion
Mar 28, 2024 (Actual)
Completion
May 31, 2027 (Estimated)
Last update posted
Jul 31, 2026

2021 – 2027

United States locations

U.S. sites
43
U.S. states
14
U.S. cities
37
Facility City State ZIP Site status
University of California Davis Comprehensive Cancer Center Sacramento California 95817 —
Smilow Cancer Hospital-Derby Care Center Derby Connecticut 06418 —
Smilow Cancer Hospital Care Center-Fairfield Fairfield Connecticut 06824 —
Smilow Cancer Hospital Care Center at Glastonbury Glastonbury Connecticut 06033 —
Smilow Cancer Hospital Care Center at Greenwich Greenwich Connecticut 06830 —
Smilow Cancer Hospital Care Center - Guilford Guilford Connecticut 06437 —
Smilow Cancer Hospital Care Center at Saint Francis Hartford Connecticut 06105 —
Yale University New Haven Connecticut 06520 —
Yale-New Haven Hospital North Haven Medical Center North Haven Connecticut 06473 —
Smilow Cancer Hospital Care Center at Long Ridge Stamford Connecticut 06902 —
Smilow Cancer Hospital Care Center-Trumbull Trumbull Connecticut 06611 —
Smilow Cancer Hospital-Waterbury Care Center Waterbury Connecticut 06708 —
UM Sylvester Comprehensive Cancer Center at Aventura Aventura Florida 33180 —
UM Sylvester Comprehensive Cancer Center at Coral Gables Coral Gables Florida 33146 —
UM Sylvester Comprehensive Cancer Center at Deerfield Beach Deerfield Beach Florida 33442 —
UF Health Cancer Institute - Gainesville Gainesville Florida 32610 —
University of Miami Miller School of Medicine-Sylvester Cancer Center Miami Florida 33136 —
UM Sylvester Comprehensive Cancer Center at Kendall Miami Florida 33176 —
UM Sylvester Comprehensive Cancer Center at Plantation Plantation Florida 33324 —
Emory University Hospital Midtown Atlanta Georgia 30308 —
Emory University Hospital/Winship Cancer Institute Atlanta Georgia 30322 —
Memorial Hospital East Shiloh Illinois 62269 —
University of Kansas Cancer Center Kansas City Kansas 66160 —
University of Kansas Cancer Center-Overland Park Overland Park Kansas 66210 —
University of Kansas Hospital-Indian Creek Campus Overland Park Kansas 66211 —
University of Kansas Hospital-Westwood Cancer Center Westwood Kansas 66205 —
Siteman Cancer Center at Saint Peters Hospital City of Saint Peters Missouri 63376 —
Siteman Cancer Center at West County Hospital Creve Coeur Missouri 63141 —
University of Kansas Cancer Center - North Kansas City Missouri 64154 —
University of Kansas Cancer Center - Lee's Summit Lee's Summit Missouri 64064 —
University of Kansas Cancer Center at North Kansas City Hospital North Kansas City Missouri 64116 —
Washington University School of Medicine St Louis Missouri 63110 —
Siteman Cancer Center-South County St Louis Missouri 63129 —
Siteman Cancer Center at Christian Hospital St Louis Missouri 63136 —
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center New York New York 10032 —
Wake Forest Baptist Health - Wilkes Medical Center Wilkesboro North Carolina 28659 —
Wake Forest University Health Sciences Winston-Salem North Carolina 27157 —
University of Oklahoma Health Sciences Center Oklahoma City Oklahoma 73104 —
UPMC Hillman Cancer Center Pittsburgh Pennsylvania 15232 —
Vanderbilt Breast Center at One Hundred Oaks Nashville Tennessee 37204 —
Vanderbilt University/Ingram Cancer Center Nashville Tennessee 37232 —
VCU Massey Comprehensive Cancer Center Richmond Virginia 23298 —
University of Wisconsin Carbone Cancer Center - University Hospital Madison Wisconsin 53792 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04345913, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 31, 2026 · Synced Oct 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT04345913 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →